Cargando…

Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma

BACKGROUND: We performed a meta-analysis to compare the efficacy and safety of anti-epidermal growth factor receptor (EGFR) therapy and non-anti-EGFR therapy in recurrent/metastatic (RM) head and neck squamous cell carcinoma (HNSCC). METHODS: The Cochrane library, WanFang Data, PubMed, Medline, VIP,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xin, Yong, Yan, Qiuyue, Yang, ChunSheng, Jiang, Fan, Guo, Wenwen, Huang, Qian, Jiang, Guan, Zhang, Longzhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320165/ https://www.ncbi.nlm.nih.gov/pubmed/30572506 http://dx.doi.org/10.1097/MD.0000000000013717

Ejemplares similares

Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Hsieh, Ronan W., et al.
Publicado: (2021)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borel, Christian, et al.
Publicado: (2020)

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
por: Pivot, X, et al.
Publicado: (2001)

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer
por: Lorch, Jochen H
Publicado: (2009)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Borcoman, Edith, et al.
Publicado: (2021)

The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma
por: Salvestrini, Viola, et al.
Publicado: (2022)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus
por: Wang, Huanhuan, et al.
Publicado: (2021)

Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells
por: Dawson, John C., et al.
Publicado: (2011)

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck
por: Russell, Jeffery S., et al.
Publicado: (2012)

Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor
por: Singh, Tripti, et al.
Publicado: (2015)

Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study
por: Liu, Zijing, et al.
Publicado: (2022)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Efficacy and Safety of Iodine-125 Brachytherapy in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wu, Chunrong, et al.
Publicado: (2020)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2021)

New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Alberti, Andrea, et al.
Publicado: (2022)

Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience
por: Pareek, Ananya, et al.
Publicado: (2021)

Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
por: Baa, Annie Kanchan, et al.
Publicado: (2023)

Treatment Sequences in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Cetuximab Followed by Immunotherapy or Vice Versa
por: Yang, Chuan-Chien, et al.
Publicado: (2022)

Osteopontin Levels in Patients with Squamous Metastatic Head and Neck Cancer
por: Maleš, Josip, et al.
Publicado: (2021)

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
por: Liu, Maobai, et al.
Publicado: (2019)

Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Kafri, Zyad, et al.
Publicado: (2012)

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03
por: Fayette, Jerome, et al.
Publicado: (2017)

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
por: Chen, Tien-Hua, et al.
Publicado: (2022)

Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and meta-analysis
por: Xu, Qiudong, et al.
Publicado: (2023)

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
por: Flanagan, Kevin C., et al.
Publicado: (2023)

Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma
por: Dean, Nichole R., et al.
Publicado: (2011)

Confluent tracheal recurrences of head and neck squamous cell carcinoma
por: Bleiberg, Benjamin Aaron, et al.
Publicado: (2019)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.
por: Stanton, P., et al.
Publicado: (1994)

Exons 19 and 21 of Epidermal Growth Factor Receptor Are Highly Conserved in Squamous Cell Cancer of the Head and Neck
por: Carlson, Matthew, et al.
Publicado: (2009)

Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck
por: Iberri, David J., et al.
Publicado: (2016)

RhoC Mediates Epidermal Growth Factor-Stimulated Migration and Invasion in Head and Neck Squamous Cell Carcinoma
por: Tumur, Zohra, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uoen5ibejt9ami4dov18r6meu0